LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), today announced strategic prioritization of late-stage ocular disease programs in allergic conjunctivitis, dry ...
Highest priority programs – BEAM-101 and ESCAPE for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency – expected to provide foundation for meaningful value creation Company to ...
Caribou Biosciences, Inc. announced a strategic shift focusing on its lead oncology programs, CB-010 and CB-011, involving workforce and cost reductions aimed at extending its cash runway into the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback